Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1200
-0.0050 (-4.00%)
Mar 4, 2026, 3:31 PM AEST
Invex Therapeutics Revenue
Invex Therapeutics had revenue of 229.08K AUD in the twelve months ending December 31, 2025, down -81.10% year-over-year. In the fiscal year ending June 30, 2025, Invex Therapeutics had annual revenue of 229.08K, down -81.10%.
Revenue
229.08K
Revenue Growth
-81.10%
P/S Ratio
41.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 229.08K | -983.17K | -81.10% |
| Jun 30, 2024 | 1.21M | 753.17K | 164.06% |
| Jun 30, 2023 | 459.09K | 276.83K | 151.90% |
| Jun 30, 2022 | 182.25K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Neurotech International | 7.07M |
| Tissue Repair | 3.26M |
| Acrux | 2.81M |
| Nexalis Therapeutics | 767.69K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |